Learn more about our technologies, company and capabilities
WuXi Biologics
Completes Multiple Global Regulatory Inspections
WuXi Biologics Completes GMP Inspection by Health Canada for Drug Substance Facility
Read More
WuXi Biologics Received First Manufacturing License from Japan and Completed 12 Global Regulatory Inspections in 2021 Year to Date
Read More
WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Certificate
Read More
WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility
Read More
WuXi Biologics Receives GMP Conformity Assessment from the Singapore Health Sciences Authority (HSA)
Read More
Jan 10-13, 2022
40th J.P. Morgan Healthcare Conference
Jan 17-19, 2022
21st Annual Peptalk
Our Regulatory Affairs team provides a quarterly summary of updates organized by agency and by topic. These updates support your efforts to stay current in our ever-changing regulatory environment.
For more information - See this Podcast
For more information on our Quality track record, please click this
infographic
.
WuXi Biologics Congratulates Amicus on U.S. FDA’s Acceptance of its Filing for AT-GAA for the Treatment of Pompe Disease
Read More
To read more about WuXi Biologics visit our
Newsletter Archive
Follow Us!